Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):387–392. doi: 10.1128/aac.40.2.387

Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers.

M Oethinger 1, S Conrad 1, K Kaifel 1, A Cometta 1, J Bille 1, G Klotz 1, M P Glauser 1, R Marre 1, W V Kern 1
PMCID: PMC163121  PMID: 8834885

Abstract

Previous reports have suggested an increasing incidence of highly fluoroquinolone-resistant Escherichia coli causing bacteremia among cancer patients on prophylactic therapy. We used genotyping by pulsed-field gel electrophoresis of chromosomal DNA digests and random amplified polymorphic DNA fingerprinting to study clonal relationships among such isolates obtained at 10 cancer centers located across Europe and the Middle East. Analysis by both methods indicated that isolates from different centers were genotypically unrelated to each other. There were five centers from which more than one individual patient isolate was available, and most demonstrated significant within-center genetic diversity of strains. Strains shared among patients could be identified at two centers. At the center with the largest number of bloodstream isolates from cancer patients available, fluoroquinolone-resistant control isolates from surgical patients and fluoroquinolone-susceptible control isolates from patients admitted to medical services during the same time period were unrelated to resistant cancer patient isolates and to each other as well. A substantial number of fluoroquinolone-resistant isolates (19 of 58) were nontypeable by pulsed-field gel electrophoresis. Fluoroquinolone resistance was commonly associated with multiple antibiotic resistance to chemically unrelated antibacterial agents irrespective of the origin of the isolates.

Full Text

The Full Text of this article is available as a PDF (275.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., O'Brien T. F., Goldstein F. W., Jones R. N. The epidemiology of bacterial resistance to quinolones. Drugs. 1993;45 (Suppl 3):24–28. doi: 10.2165/00003495-199300453-00006. [DOI] [PubMed] [Google Scholar]
  2. Arbeit R. D., Arthur M., Dunn R., Kim C., Selander R. K., Goldstein R. Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J Infect Dis. 1990 Feb;161(2):230–235. doi: 10.1093/infdis/161.2.230. [DOI] [PubMed] [Google Scholar]
  3. Bauernfeind A., Abele-Horn M., Emmerling P., Jungwirth R. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother. 1994 Dec;34(6):1074–1076. doi: 10.1093/jac/34.6.1074. [DOI] [PubMed] [Google Scholar]
  4. Böhm H., Karch H. DNA fingerprinting of Escherichia coli O157:H7 strains by pulsed-field gel electrophoresis. J Clin Microbiol. 1992 Aug;30(8):2169–2172. doi: 10.1128/jcm.30.8.2169-2172.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carratalá J., Fernández-Sevilla A., Tubau F., Callis M., Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995 Mar;20(3):557–563. doi: 10.1093/clinids/20.3.557. [DOI] [PubMed] [Google Scholar]
  6. Cometta A., Calandra T., Bille J., Glauser M. P. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med. 1994 Apr 28;330(17):1240–1241. doi: 10.1056/NEJM199404283301717. [DOI] [PubMed] [Google Scholar]
  7. Cometta A., Zinner S., de Bock R., Calandra T., Gaya H., Klastersky J., Langenaeken J., Paesmans M., Viscoli C., Glauser M. P. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995 Feb;39(2):445–452. doi: 10.1128/aac.39.2.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cookson B., Johnson A. P., Azadian B., Paul J., Hutchinson G., Kaufmann M., Woodford N., Malde M., Walsh B., Yousif A. International inter- and intrahospital patient spread of a multiple antibiotic-resistant strain of Klebsiella pneumoniae. J Infect Dis. 1995 Feb;171(2):511–513. doi: 10.1093/infdis/171.2.511. [DOI] [PubMed] [Google Scholar]
  9. Courvalin P. Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother. 1990 May;34(5):681–684. doi: 10.1128/aac.34.5.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grundmann H., Schneider C., Hartung D., Daschner F. D., Pitt T. L. Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa. J Clin Microbiol. 1995 Mar;33(3):528–534. doi: 10.1128/jcm.33.3.528-534.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heisig P., Schedletzky H., Falkenstein-Paul H. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 1993 Apr;37(4):696–701. doi: 10.1128/aac.37.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heisig P., Tschorny R. Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro. Antimicrob Agents Chemother. 1994 Jun;38(6):1284–1291. doi: 10.1128/aac.38.6.1284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hibbert-Rogers L. C., Heritage J., Gascoyne-Binzi D. M., Hawkey P. M., Todd N., Lewis I. J., Bailey C. Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward. J Antimicrob Chemother. 1995 Jul;36(1):65–82. doi: 10.1093/jac/36.1.65. [DOI] [PubMed] [Google Scholar]
  14. Kern W. V., Andriof E., Oethinger M., Kern P., Hacker J., Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994 Apr;38(4):681–687. doi: 10.1128/aac.38.4.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kresken M., Hafner D., Mittermayer H., Verbist L., Bergogne-Bérézin E., Giamarellou H., Esposito S., van Klingeren B., Kayser F. H., Reeves D. S. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection. 1994;22 (Suppl 2):S90–S98. doi: 10.1007/BF01793572. [DOI] [PubMed] [Google Scholar]
  16. Kresken M., Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother. 1988 Aug;32(8):1285–1288. doi: 10.1128/aac.32.8.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Linhardt F., Ziebuhr W., Meyer P., Witte W., Hacker J. Pulsed-field gel electrophoresis of genomic restriction fragments as a tool for the epidemiological analysis of Staphylococcus aureus and coagulase-negative staphylococci. FEMS Microbiol Lett. 1992 Aug 15;74(2-3):181–185. doi: 10.1016/0378-1097(92)90426-o. [DOI] [PubMed] [Google Scholar]
  18. Madico G., Akopyants N. S., Berg D. E. Arbitrarily primed PCR DNA fingerprinting of Escherichia coli O157:H7 strains by using templates from boiled cultures. J Clin Microbiol. 1995 Jun;33(6):1534–1536. doi: 10.1128/jcm.33.6.1534-1536.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Oram M., Fisher L. M. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother. 1991 Feb;35(2):387–389. doi: 10.1128/aac.35.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ouabdesselam S., Hooper D. C., Tankovic J., Soussy C. J. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother. 1995 Aug;39(8):1667–1670. doi: 10.1128/aac.39.8.1667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Peña C., Albareda J. M., Pallares R., Pujol M., Tubau F., Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995 Feb;39(2):520–524. doi: 10.1128/aac.39.2.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Richard P., Delangle M. H., Merrien D., Barillé S., Reynaud A., Minozzi C., Richet H. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis. 1994 Jul;19(1):54–59. doi: 10.1093/clinids/19.1.54. [DOI] [PubMed] [Google Scholar]
  23. Römling U., Grothues D., Heuer T., Tümmler B. Physical genome analysis of bacteria. Electrophoresis. 1992 Sep-Oct;13(9-10):626–631. doi: 10.1002/elps.11501301128. [DOI] [PubMed] [Google Scholar]
  24. Struelens M. J., Bax R., Deplano A., Quint W. G., Van Belkum A. Concordant clonal delineation of methicillin-resistant Staphylococcus aureus by macrorestriction analysis and polymerase chain reaction genome fingerprinting. J Clin Microbiol. 1993 Aug;31(8):1964–1970. doi: 10.1128/jcm.31.8.1964-1970.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tenover F. C., Arbeit R. D., Goering R. V., Mickelsen P. A., Murray B. E., Persing D. H., Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995 Sep;33(9):2233–2239. doi: 10.1128/jcm.33.9.2233-2239.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vila J., Ruiz J., Marco F., Barcelo A., Goñi P., Giralt E., Jimenez de Anta T. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother. 1994 Oct;38(10):2477–2479. doi: 10.1128/aac.38.10.2477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wang G., Whittam T. S., Berg C. M., Berg D. E. RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains. Nucleic Acids Res. 1993 Dec 25;21(25):5930–5933. doi: 10.1093/nar/21.25.5930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. van Belkum A. DNA fingerprinting of medically important microorganisms by use of PCR. Clin Microbiol Rev. 1994 Apr;7(2):174–184. doi: 10.1128/cmr.7.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES